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Abstract 
We measured haemagglutination inhibiting (HI) serum antibody titers to vaccine matched A/H1N1 influenza virus 
strain and to the new pandemic 2009 A/H1N1 (pH1N1) virus in two groups of volunteers prior and after 2003/2004 
or 2007/2008 influenza seasonal vaccine administration. The responses were examined considering the overall 
volunteers studied in the two winters (144 and 79, respectively) and grouping those subjects in birth cohort classes 
(1903–1919; 1920–1957; 1958–1977). Before vaccination, HI antibody titers were found in all the groups examined 
and, on comparing the different age-groups, titers were higher in the younger groups as compared with the oldest 
against the A/H1N1 seasonal strains but titers were higher in the oldest as compared with the younger ones against 
the pH1N1 strain. Vaccination induced significant increases in HI titers against the matched A/H1N1 vaccine strains 
in all the groups examined. The responses satisfied the EMEA criteria and were higher in the youngest volunteers as 
compared with older groups. Increases were also found in the level of cross-reactive HI antibodies to the new 
pandemic 2009 A/H1N1 virus although in most instances the requirements of the EMEA were not met.
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1. Introduction 
In the Spring 2009, a novel A/H1N1 influenza virus emerged (pH1N1), and on June 11, 2009, the 
WHO declared that a pandemic was in progress >1@. Although the antigenic regions of the HA and NA 
surface proteins of the new pH1N1 were found to be divergent with respect to recently circulating 
seasonal H1N1 influenza viruses >2@, the possibility that seasonal influenza vaccine might offer protection 
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against pH1N1 virus was considered, and conflicting results were obtained in different studies. 
 
Immunization with seasonal vaccines was found to result in small or no increase in antibodies against 
the novel pH1N1 >3-8@. Null or protective effects or increased risk were observed studying seasonal 
vaccine effectiveness against pH1N1-associated illness >9-13@. Few studies evaluated the effects of 
seasonal vaccination on infection with pH1N1 viruses in established animal models and again the results 
were discrepant >14, 15@.  
 
In order to increase these observations, using stored serum specimens collected during previous 
influenza vaccine immunogenicity studies, we assessed serological responses to the vaccine A/H1N1 
strain and the level of cross-reactive antibodies to the novel A/H1N1 pandemic virus in volunteers of 
different groups of age before and after they had been vaccinated with the 2003/2004 or with the 
2007/2008 influenza season vaccines. 
2. Methods 
2.1. Study population and vaccination 
A total of 144 and 79 volunteers were immunized with a single dose of commercially available 
inactivated trivalent MF59-adjuvanted influenza vaccine respectively in November 2003 
(A/Moscow/10/99 (H3N2), A/New Caledonia/20/99 (H1N1) and B/Hong Kong/330/01) (Fluad, Novartis) 
and November 2007 (A/Wisconsin/67/05 (H3N2), A/Solomon Islands/3/06 (H1N1) and 
B/Malaysia/2506/04) (Fluad, Novartis). Blood samples were drown before and one month after 
immunization and stored at –30 °C until used. 
2.2. Influenza antibody titration 
Haemagglutination-inhibiting (HI) antibody titers were determined by a standard microtiter method 
using influenza virus antigens prepared from the allantoic fluids of infected eggs and 0.5% turkey 
erythrocytes.  
 
Pre- and post-vaccination sera from each volunteer were tested simultaneously for HI titers against the 
A/H1N1 component of the trivalent influenza vaccine utilized for the immunization (A/New 
Caledonia/20/99 (hereafter A/New Caledonia) for 2003/2004 and A/Solomon Islands/3/06 (hereafter 
A/Solomon) for 2007/2008 winter season) and against the new pandemic A/H1N1 virus, using as antigen 
the newly isolated A/Italy/05/09 (H1N1) (deposited in GeneBank under accession no. GQ251032 to 
GQ251039), antigenically and genetically correlated with the pH1N1 prototype, A/California/4/09. All 
sera were treated with receptor-destroying enzyme and heat-inactivated at 56°C for 30 min to remove 
non-specific inhibitors. 
2.3 Vaccine immunogenicity and statistical analysis 
Vaccine immunogenicity was evaluated by comparing antibody titers in blood samples collected 
before and 30 days after vaccination, as protection rate (number of volunteers showing HI titers 40, 
considered to be associated with protection from influenza infection) >16@, geometric mean titers (GMT) 
(the first dilution for antibody titration was 1:10 and any titer <10 was considered 5 for GMT calculation), 
mean fold increase (MFI) of GMT (ratio of post-immunization to pre-immunization GMT) and positive 
responses (number of people with a fourfold or more rise in titer in subjects with antibodies before 
vaccination or from <10 to 40 in subjects seronegative before vaccination). Moreover the results of 
vaccine immunogenicity were assessed according to the post-vaccination requirements of European 
52  A.M. Iorio et al. / Procedia in Vaccinology 4 (2011) 50–58
Commission for the evaluation of interpandemic influenza vaccines in elderly or non elderly people (post-
vaccination seroprotection 60% or 70%, MFI of GMT 2 or 2.5, positive responses 30% or 40% 
respectively) >17@. 
 
Differences in the frequency of qualitative variables were analyzed by Student’s t-test (comparison of 
GMT values) and Chi-square test (comparison of number of people with protective antibody titers and 
positive responses). HI titers were also corrected for pre-vaccination status as described by Beyer et al. 
>18@. 
3. Results  
3.1 Characteristics of the study subjects 
Table 1 reports the demographic characteristics, previous influenza vaccinations and health status of 
the two groups of volunteers studied respectively in the winter season 2003/2004 (144 people) and 
2007/2008 (79 people). The subjects were examined both considering the overall population and splitting 
them into groups according to the birth date and the characteristics of the A/H1N1 influenza virus causing 
the probably A/H1N1 first infection in their life (1903-1919, 1920-1957 and 1958-1977). All the 
volunteers born before 1958 were institutionalized people and had a history of previous influenza 
vaccinations. A high percentage of them had chronic diseases (range 93 to 98%) and continuous drug 
treatment (range 95 to 100%). Of the two groups of people born after 1957, only those vaccinated in the 
winter 2003/2004, working in the state police, had a history of previous influenza vaccination (73%) and 
in a low percentage showed chronic disease or continuous drug use. 
 
Table 1. Characteristics of the study population 
 
Winter 
season Birth cohort 
N. of 
subjects 
Mean age 
(range) 
% 
previously 
vaccinated 
% chronic 
disease* 
% of long term 
drug 
treatment** 
2003/2004 
1903-1977 
(Total) 144 
69 
(31-98) 95 80 82 
1903-1919 55 90 (84-98) 100 95 95 
1920-1957 63 76 (57-83) 100 95 98 
1958-1977 26 40 (31-46) 73 1 15 
       
2007/2008 
1903-1977 
(Total) 79 
69 
(30-102) 86 81 84 
1903-1919 18 92 (88-102) 100 93 100 
1920-1957 50 79 (61-87) 100 98 100 
1958-1977 11 35 (30-46) 0 0 0 
 
* The most frequently chronic diseases were hearth condition and nervous system disorders 
** The drugs most frequently used were antihypertensive/inotropic drugs and benzodiazepines 
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3.2 HI antibody response to the A/H1N1 component of the 2003/2004 (A/New Caledonia/20/99) or 
2007/2008 (A/Solomon Islands/3/06) influenza vaccine 
The results from comparing serum antibody titers before and one month after vaccination are reported 
in Table 2. Before vaccination HI antibody titers against the matched A/H1N1 vaccine strain were found 
in the volunteers both considering the overall population and the subjects divided in groups according to 
their age. The HI pre-vaccination titers were generally higher in the subjects immunized in the 2003/2004 
winter as compared with those immunized in the 2007/2008 winter, probably because of a likely higher 
pre-vaccination exposure to A/New Caledonia strain, the 2003/2004 A/H1N1 vaccine component. 
Considering the overall population the percentages of protected people were 39.6 vs 17.7 and the values 
of GMT 24.9 vs 9.3, respectively against A/New Caledonia and A/Solomon. No differences were found 
in the two winters among the three age groups. 
 
Vaccine administration induced statistically significant increases in the number of seroprotected 
persons and in the values of GMT both in the overall population and in subjects divided by age (Table 2). 
The responses satisfied all the three EMEA requirements >17@ with the exception of the value of positive 
responses in the group of the oldest people (age group 1903-1919) in the winter season 2003/2004 (20.0% 
positive responses). 
 
Table 2. HI antibody response against the matched A/H1N1 vaccine strain in people vaccinated with trivalent influenza vaccine in 
the winter season 2003/2004 or 2007/2008  
Winter 
Season Age group % Ab 40 GMT  
A/H1N1 
antigen (N) Pre-vacc. Post-vacc. 
Pre-vacc.  
(95% CI) 
Post-vacc. 
 (95% CI) MFI 
GMT corrected # 
(95% CI) 
% positive 
responses 
2003/2004 
A/New 
Caledonia 
1903-1977 
(144)
Total
39.6 77.8** 24.9 (19.3-32.2) 
72.5** 
(55.4-94.8) 2.9 
29.9 
(23.5-36.9) 31.2 
1903-1919 
(55) 32.7 70.9** 
24.0 
(17.3-33.2) 
47.3** 
(33.7-66.5) 2.0 
14.0 
(11.1-17.6) 20.0 
1920-1957 
(63) 39.7 76.2** 
21.8 
(15.5-30.7) 
61.6** 
(43.3-87.7) 2.8 
26.4 §§ 
(19.7-35.5) 31.7 
1958-1977 
(26) 53.8 96.2** § 
37.4 
(15.6-89.5) 
265.0** §§ 
(151.5-463.3) 7.1 
175.5 §§ 
(103.3-298.2) 53.8§ 
         
2007/2008 
 
A/Solomon  
1903-1977 
(79)
Total 
17.7 73.4** 9.3 (6.8-12.7) 
58.3** 
(36.7-92.7) 6.2 
38.2 
(25.3-57.8) 60.7 
1903-1919 
(18) 11.1 77.8** 
7.6 
(4.5-13.0) 
61.1* 
(26.6-140.3) 8.0 
43.3 
(21.3-88.3) 72.2 
1920-1957 
(50) 18.0 70.0** 
9.2 
(6.2-13.6) 
45.3** 
(26.3-78.2) 4.9 
29.0 
(18.2-46.1) 56.0 
1958-1977 
(11) 27.3 81.8* 
13.7 
(6.0-31.4) 
170.4 * § 
(44.5-651.9) 12.4 
160.0 §§ 
(41.8-611.5) 63.6 
*: p<0.05; **: p<0.01 comparing pre- e post-vaccination titers  
§ (p<0.05); §§ (p<0.01) comparing 1920-1957 and 1958-1977 age groups with 1903-1919 
# post-vaccination GMT values corrected for pre-vaccination status 
 
Comparing the results obtained in the two winters in volunteers divided in groups according to the 
birth date, the responses of the youngest people (age cohort 1958/1977) were higher, although not always 
at statistically significant levels, as compared with those of the older people groups (especially age cohort 
1903/1919). In accordance with previous work showing that high antibody titers may negatively influence 
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the production of new antibodies upon vaccination >18@, the post-vaccination HI antibody responses were 
lower against A/New Caledonia as compared with values found against A/Solomon strain. Indeed the 
positive responses and the MFI of GMT against the matched A/H1N1 vaccine strain were for the total 
population 31.2% (range among age-groups, 20.0 to 53.8%) vs 60.7% (range 56.0 to 72.2%) and 2.9 
(range 2.0 to 7.1) vs 6.2 (range 4.9 to 12.4) respectively for people vaccinated in the winter 2003/2004 
(A/New Caledonia) or 2007/2008 (A/Solomon). 
 
Since the pre-vaccination status against the two A/H1N1 vaccine strains was not fully comparable, we 
analyzed post-vaccination GMT values normalized for pre-vaccination status >18@. Again, younger 
individuals gave better responses than the older volunteers in both winters under investigation. Responses 
against A/New Caledonia and A/Solomon became comparable for the 1920–1957 and 1958–1977 age 
groups, but continued to be lower in the volunteers of the age cohort 1903–1919 vaccinated in the 
2003/2004 winter as compared with those immunized in the 2007/2008 season (14.0 vs 43.3, p<0.01). 
 
3.3 HI antibody response to the new 2009 A/H1N1 pandemic virus after 2003/2004 or 2007/2008 
influenza vaccine administration 
Determination of HI antibody titers against the 2009 pH1N1 virus evidenced, in accordance with 
previous published data >3, 4, 6, 7, 19-22@, that antibodies were present before vaccination (Table 3).  
 
Table 3. HI antibody response against the new 2009 pH1N1 pandemic influenza strain in people vaccinated with trivalent influenza 
vaccine in the winter season 2003/2004 or 2007/2008 
Winter 
Season Age group  % Ab 40 GMT  
A/H1N1 
antigen (N) Pre-vacc. Post-vacc. 
Pre-vacc.  
(95% CI) 
Post-vacc. 
(95% CI) MFI 
GMT corrected # 
(95% CI) 
% positive 
responses 
2003/2004 
pH1N1  
 
1903-1977 
(144)  
Total 
32.6 45.1* 17.7 (13.7-22.8) 
27.3 
(21.2-35.3) 1.5 
9.6 
(8.3-11.1) 11.8 
1903-1919 
(55) 52.7 61.8 
33.4 
(21.7-51.4) 
46.2 
(31.2-68.3) 1.4 
9.8 
(8.3-11.7) 10.9 
1920-1957 
(63) 25.4§§ 36.5 
13.4 §§ 
(9.9-18.2) 
20.6** 
(14.6-29.0) 1.5 
8.8 
(7.1-10.9) 9.5 
1958-1977 
(26) 7.7§§ 30.7 
9.0 §§ 
(6.2-12.9) 
17.8* § 
(10.2-31.3) 2.0 
10.6 
(6.7-16.9) 19.2 
         
2007/2008 
 
pH1N1  
1903-1977 
(79)  
Total 
27.8 55.7** 18.4 (13.3-25.4) 
36.4** 
(24.7-53.7) 2.0 
9.9 
(8.0-12.2) 24.0 
1903-1919 
(18) 55.6 88.8 
48.0 
(27.3-84.5) 
123.0* 
(61.3-246.5) 2.6 
13.7 
(8.9-21.0) 44.4 
1920-1957 
(50) 24.0 § 56.0** §§ 
17.1 §§ 
(12.2-24.0) 
30.8** §§ 
(21.0-45.1) 1.8 
10.1 
(8.1-12.8) 16.0 
1958-1977 
(11) 0.0 §§ 18.2 §§ 
5.3 §§ 
(4.5-6.2) 
10.6 § 
(5.2-22.0) 2.0 
10.7 
(5.2-22.0) 27.2 
 
*: p<0.05; **: p<0.01 comparing pre- and  post-vaccination titers  
§ (p<0.05); §§ (p<0.01) comparing 1920-1957 and 1958-1977 age groups with 1903-1919 
# post-vaccination GMT values corrected for pre-vaccination status 
 
Pre-vaccination HI antibody titers against pH1N1 40, considered to be protective for epidemic 
influenza strains >16@, were present in the 32.6% of the 144 people vaccinated in the 2003/2004 winter 
and in 27.8% of the 79 people vaccinated in the 2007/2008 winter. On considering people grouped 
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according to the birth dates, the pre-vaccination percentages of protected people and values of GMT 
found in the oldest people (cohort people born 1903-1919), were significantly higher as compared with 
titers of people of the two other younger  groups in both winters. Moreover, as previously observed >3, 4, 
19, 20@, the pre-vaccination HI titers of the oldest volunteers against the pH1N1 strain were in general 
higher than those found against the matched seasonal H1N1 vaccine strain (Table 2). Following 
vaccination, we observed slight increases, which were statistically significant in some instances, in the HI 
titers for each winter in the overall population and in the three age groups. On examining post-vaccination 
parameters in the winters 2003/2004 and 2007/2008 in the overall population, HI titers 40 were present 
in 45.1% and 55.7%, the values of the MFI of GMT were 1.5 and 2.0 and 11.8% and 24.0% of the people 
showed positive responses. In most instances the EMEA criteria >17@ were not satisfied. 
 
Comparing the different age groups, the post-vaccination HI titers generally tended to be higher in the 
oldest groups. In particular, the responses of people born in 1903–1919 and vaccinated for the winter 
2007/08 were statistically significant higher as compared with those of the two other younger age groups 
and met all the three EMEA requirements (89.0% protected people, MFI of GMT 2.6 and positive 
responses 44.4%). Moreover, in accordance with the data previously reported against the matched 
A/H1N1 seasonal vaccine strains (Table 2), this group gave better responses as compared with the same 
age group vaccinated in the winter 2003/2004. The GMT values corrected for pre-vaccination status 
confirmed this tendency, although the values were found to be significantly different only at the lower 
level (13.7 vs 9.8, p<0.05). 
 
4. Discussion  
We examined the possibility that seasonal influenza vaccines may induce cross-reactive antibody 
response to the new 2009 pH1N1 pandemic virus by analyzing two groups of volunteers vaccinated in the 
winter 2003/2004 (144 people) or 2007/2008 (79 people). The subjects were studied, as overall 
population or divided in groups according to their ages (1903–1919; 1920–1957; 1958–1977) (Table 1), 
for HI antibody responses against the seasonal A/H1N1 strain present in the vaccine used and against the 
new 2009 pH1N1 virus. 
 
The results obtained suggest that influenza immunization with seasonal trivalent inactivated vaccines 
may induce cross-reactive HI antibody responses to novel 2009 pH1N1 virus in different age groups, 
although much lower than those induced to the matched vaccine strain. 
 
The participants to the study were found to be able to mount positive and adequate responses since 
vaccine administration induced statistically significant increases in HI antibody titers against the matched 
A/H1N1 2003/2004 (A/New Caledonia) and 2007/2008 (A/Solomon) vaccine strains (Table 2). The 
responses usually satisfied the EMEA criteria in both groups examined as an overall population or when 
splitted in cohorts according to their birth dates. According to previous data >23@ younger people, i.e., 
born after 1957, gave better responses as compared with older volunteers. Moreover, in most instances 
the responses were higher in subjects vaccinated with A/Solomon as compared with responses of people 
vaccinated with A/New Caledonia. These differences may be attributable to general differences in 
vaccine formulation or viral antigenicity or to differences in the immune responses of the volunteers. 
Indeed, considering the post-vaccination GMT values, corrected for pre-vaccination status, the 
differences persisted only for the oldest group of volunteers (1903-1919), suggesting, at least for this age 
group, an higher ability to give an immune response to A/Solomon as compared to A/New Caledonia. In 
accordance with these data, Marcelin et al. >7@ found a higher seroconversion rate in old individuals after 
vaccination with A/Solomon as compared with vaccination with A/Brisbane/59/2002 (H1N1).  
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HI antibody titers determination against the new 2009 pH1N1 virus showed that a substantial 
proportion of older adults had pre-existing immunity to 2009 pH1N1 virus (Table 3). Considering the 
total of 223 volunteers examined in the two winters (people born between 1903 and 1977) 69 of them 
(30.9%) had pre-existing HI antibody titers 40, considered to be protective for epidemic influenza 
strains >16@, against pH1N1. Examining the 223 volunteers divided in groups according to the birth date 
the percentages with protective antibody titers were 53.4% (39/73) for those born 1903-1919, 24.7% 
(28/113) for the age group 1920-1957 and 5.4% (2/37) for volunteers born 1958-1977. These results are 
in accordance with other sero-prevalence studies >3, 4, 19-21@, and with recent data obtained, as ours, in 
Italy >22@, showing an age-dependent increase in the proportion of older individuals with pre-existing 
antibody titers to 2009 pH1N1 virus. Moreover, they reinforce the hypothesis that the higher rate of cross-
reactive antibodies in the older population may be due to cross reactivity generated from exposure to the 
1918 H1N1 virus or related H1N1 strains. Recent studies confirm the presence of cross-reactive antigenic 
sites in the HA of pH1N1 and in the prototype strain of 1918 H1N1 influenza virus strain >24@. 
 
Seasonal influenza vaccine administration induced increases in HI antibody titers against pH1N1, 
although in most instances the values suggested by the EMEA for acceptability of seasonal influenza 
vaccine >17@ were not reached. Following vaccination and considering the total population in each of the 
two winters studied, 2003/2004 and 2007/2008, the percentages of positive responses were respectively 
11.8% and 24.0% and those of seroprotected people 45.1% and 55.7%.  
 
Particularly interesting were the results observed in the group of people born in 1903–1917 that were 
examined in the winter 2007/2008. The responses of this group of oldest volunteers were significantly 
higher or tended to be better as compared with the corresponding age-group vaccinated in the winter 
2003/2004, both against A/H1N1 matched vaccine virus (Table 2) and pH1N1 (Table 3). The different 
responses might suggest that the volunteers born between 1903-1917 examined in the winters 2007/2008 
probably represent a more selected group of elderly people, capable of longer surviving and with a 
possible lower degree of age-associated alteration of the immune system, as compared with volunteers 
born between 1903–1917 and examined 5 years before in the winter 2003/2004 >25@. 
 
In conclusion the present data, obtained by measuring HI antibody titers as a surrogate marker of host 
protection, support the idea that seasonal vaccination may confer some protection against the new 2009 
pH1N1 virus, as evidenced in some, but not others clinical studies >9-13@. Moreover the presence of pre-
existing immunity against the new 2009 pH1N1 virus in the older groups and the increases, although 
limited, of humoral immunity against pH1N1 virus observed after influenza seasonal vaccination, might, 
at least in part, have contributed to the low pH1N1 attack rate reported in those above 65 years, generally 
the risk group with the highest percentage of vaccinated subjects >26@. 
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